3M Moves To Acquire Medical Company -- WSJ
03 Mai 2019 - 9:02AM
Dow Jones News
By Colin Kellaher
This article is being republished as part of our daily
reproduction of WSJ.com articles that also appeared in the U.S.
print edition of The Wall Street Journal (May 3, 2019).
3M Co. on Thursday said it agreed to buy wound-care company
Acelity Inc. from an investor group for about $4.3 billion as the
manufacturing and technology conglomerate continues to build its
health-care business.
The St. Paul, Minn., company is buying Acelity from
private-equity firm Apax Partners and Canadian pension giants
Canada Pension Plan Investment Board and Public Sector Pension
Investment Board for a total enterprise value of about $6.7
billion, including the assumption of roughly $2.4 billion in
debt.
Acelity last month filed for an initial public offering as KCI
Holdings Inc., more than seven years after the buyout group
acquired the company, then known as Kinetic Concepts Inc., in a
deal valued at about $6.3 billion.
Since then, KCI has transformed into a company focused on
advanced wound care and specialty surgical applications through a
series of acquisitions and divestitures.
3M said Acelity, which complements its health-care business,
posted revenue of $1.5 billion and adjusted earnings before
interest, taxes, depreciation and amortization of $441 million in
2018. The company in March said it expected its health-care segment
to generate annual revenue of $7 billion.
"This acquisition bolsters our Medical Solutions business and
supports our growth strategy to offer comprehensive advanced and
surgical wound-care solutions to improve outcomes and enhance the
patient and provider experience," said Mike Roman, 3M's chief
executive.
3M earlier this year acquired the technology business of
health-care-technology provider M*Modal for a total enterprise
value of $1 billion, expanding the capabilities of its
health-information-systems business.
3M said the Acelity purchase price represents a multiple of
15-times 2018 adjusted Ebitda, or 11-times the expected first-year
Ebitda after factoring in anticipated cost savings.
The company said it expects the deal will add 25 cents a share
to adjusted earnings in the first 12 months, but noted it will
reduce reported per-share earnings by 35 cents over the same
period.
As a result of the transaction, 3M lowered its planned share
repurchases for this year to $1 billion to $1.5 billion from a
prior target of $2 billion to $4 billion.
3M said it expects to complete the transaction, which it will
finance with cash on hand and the issuance of new debt, in the
second half.
S&P Global Ratings on Thursday affirmed its "AA-" credit
rating on 3M but changed its outlook to negative from stable,
citing the increased leverage from the Acelity deal and 3M's
weaker-than-expected first-quarter earnings.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 03, 2019 02:47 ET (06:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
3M (NYSE:MMM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
3M (NYSE:MMM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024